Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 2Retinoblastoma 2Lung Neoplasms 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Sjogren's Syndrome 1Scleroderma, Systemic 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Recurrence 1Psoriasis 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Multiple Sclerosis 1Melanoma 1Lymphatic Metastasis 1Lupus Erythematosus, Systemic 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Dermatomyositis 1Crohn Disease 1Colorectal Neoplasms 1

Interventions

pembrolizumab 2poly(I).poly(c12,U) 1liposomal doxorubicin 1Platinum Compounds 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Bevacizumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Cancer Recurrent × Platinum Compounds × 1 year × Clear all
NCT07295132 2025-12-19

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Asan Medical Center

Phase 2 Not yet recruiting
160 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡